FDA Approves 23andMe’s $199 Genetic Tests for Risk of Late-onset Alzheimer’s Disease

FDA Approves 23andMe’s $199 Genetic Tests for Risk of Late-onset Alzheimer’s Disease
Americans who want to assess their risk for late-onset Alzheimer’s disease may now order $199 genetic tests, now that the U.S. Food and Drug Administration (FDA) has allowed 23andMe to sell such genetic analyses directly to consumers. Besides Alzheimer’s, the Mountain View, Calif., company has received authorization for reports on Parkinson’s disease, hereditary thrombophilia, celiac disease and five other

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *